Cooperative Agreement U01CA294154
- This $204,027 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting the Weill Medical College of Cornell University in expanding single-cell and spatial technologies to link clonal genotypes with phenotypes during cancer evolution. The grant aims to develop advanced single-cell methods that can capture multiple data modalities, including genotypes, transcriptomes, methylomes, and protein expression, to better understand how somatic...
- The National Cancer Institute (NCI) awarded a $591,468 Project Grant on August 6, 2025 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Research Foundation for the State University of New York (SUNY Oswego). The funding supports research to develop explainable machine learning models based on deep cancer pathophysiology to improve cancer diagnosis, risk stratification, and therapeutic recommendations. The project aims to address key gaps in integrating heterogeneous...
- This federal Project Grant award, valued at $401,829.00 and awarded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports innovative research by Weill Medical College of Cornell University to develop transformative methods for high-throughput single-cell mapping of DNA-binding proteins. The project, titled "Precision Single-Cell Mapping of Chromatin-Associated Protein Activity by Molecular Footprinting to Chart Disruptions to Gene Regulation...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- The U.S. National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a period of performance from February 1, 2025 to January 31, 2027, will fund research to study the role of aberrant mRNA splicing in cancer cell heterogeneity and its potential as a target for immunotherapeutic strategies. The research aims to utilize advanced computational and single-cell approaches...
- The National Cancer Institute awarded a Project Grant under CFDA 93.396 - Cancer Biology Research to Cornell University in the amount of $576,337 on August 11, 2025. The project, titled "The Integrated Mechanobiology and Glycobiology of Bone Metastasis", aims to study how the mineral content of bone matrix influences early-stage metastasis of breast cancer cells. The research team will investigate the mechanisms by which bone mineral density regulates the behavior of disseminated tumor...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $285,599 Project Grant to Sinopia Biosciences Inc., a San Diego-based company specializing in computational drug discovery and metabolomics research. The grant will support the development of a metabolomics-enabled AI/ML platform for identifying new treatments to enhance drug sensitivity in cancer. The project aims to leverage high-throughput omics technologies, machine learning, and a chemical library of ~3,300...
- The National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), has awarded a $398,398 Cooperative Agreement to Baylor College of Medicine to advance protein isoform analysis through an integrated computational framework. The project aims to address challenges in accurately identifying and quantifying protein isoforms from mass spectrometry-based proteomic data, which is critical for understanding cancer biology and developing targeted therapies. The award, with a...
The National Cancer Institute (NCI), a component of the National Institutes of Health, awarded a $413,509 Cooperative Agreement to Cornell University under the Cancer Biology Research program (CFDA 93.396). The project aims to develop a deep learning-based pipeline named PIONEER to generate comprehensive 3D models of the human interactome, addressing a key unmet need in precision oncology. By integrating PIONEER with the PREPPI pipeline, the project will generate atomic-resolution 3D models for the entire human interactome. This 3D-structurally-informed framework will identify spatial clusters of cancer mutations and dysregulated network modules/pathways, advancing the understanding of cancer biology and enabling improved prevention, diagnosis, and treatment strategies. The project period runs from Aug 4, 2025 to Jul 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/18/25 | ||
| Not listed | $413.5k | 8/4/25 |